eFFECTOR Therapeutics
Latest round
- Series C
Last raised
- Jul 2017
Total raised
- $116M
Investors
- 14
About eFFECTOR Therapeutics
Founded in 2012 and based in California, US, eFFECTOR Therapeutics, Inc. is a biopharmaceutical company that develops selective translation regulators drugs for the treatment of cancer and other serious diseases. The translation regulation helps to understand genes that are translationally dysregulated. Davide Ruggero, Kevan Shokat, Kevin Eastwood, Siegfried Reich, and Steve Worland are the co-founders of the company. eFFECTOR’s lead product candidate, tomivosertib, is an MNK 1/2 inhibitor. KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivorsertib. The firm's second product candidate, Zotatifin, eFFECTOR’s small molecule inhibitor of eIF4A, is in the dose-escalation portion of a Phase 1/2 trial. The organization has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. The eFFECTOR’s product candidates are designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress, and inflammatory responses, as well as cell proliferation. The company's STRI (Selective Translation Regulator Inhibitor) product candidate targets the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2).
Who invested in eFFECTOR Therapeutics
14 investors across 5 rounds
See all investors in eFFECTOR Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about eFFECTOR Therapeutics
Who invested in eFFECTOR Therapeutics?
eFFECTOR Therapeutics has 14 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has eFFECTOR Therapeutics raised?
eFFECTOR Therapeutics has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did eFFECTOR Therapeutics last raise money?
eFFECTOR Therapeutics's most recent round on record is a Series C, in Jul 2017.
What does eFFECTOR Therapeutics do?
Founded in 2012 and based in California, US, eFFECTOR Therapeutics, Inc.
Where is eFFECTOR Therapeutics headquartered?
eFFECTOR Therapeutics is headquartered in San Diego, US.
Which VCs invest in companies like eFFECTOR Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at eFFECTOR Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like eFFECTOR Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.